ASCO 2014 – Colorectal and Head & Neck Cancer

Chemotherapy Plus Bevacizumab or Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Racial Differences in KRAS/BRAF Mutation Rates and Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Early Predictors of Overall Survival in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

The Current Status of Biomarkers in Use for the Treatment of Patients with mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Updated Results of the SOFT Study

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

mCRC Daily News from ASCO 2014: May 30, 2014 - Preview of Key Topics

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Rechallenge with Anti-EGFR Therapy

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

BRAF + MEK Inhibitors in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

BRAF Inhibitor + Cetuximab in mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Second-Line Therapies in KRAS–Wild-Type mCRC

ASCO 2014 – Colorectal and Head & Neck Cancer, ASCO

Conference Correspondent

Page 2 of 3

1
2
3